Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties

The use of Lenalidomide (LEN), to reverse tumor-mediated immune suppression and amplify multiple myeloma-specific immunity is currently being explored. Particularly, LEN effects on dendritic cells (DCs) are still unclear. In this study, we investigated the potential effect of LEN on DC differentiati...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Federica, Vescovini, Rosanna, Bolzoni, Marina, Marchica, Valentina, Storti, Paola, Toscani, Denise, Accardi, Fabrizio, Notarfranchi, Laura, Dalla Palma, Benedetta, Manferdini, Cristina, Manni, Sabrina, Todaro, Giannalisa, Lisignoli, Gina, Piazza, Francesco, Aversa, Franco, Giuliani, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581092/
https://www.ncbi.nlm.nih.gov/pubmed/28881793
http://dx.doi.org/10.18632/oncotarget.18085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581092/
https://www.ncbi.nlm.nih.gov/pubmed/28881793
http://dx.doi.org/10.18632/oncotarget.18085

Ejemplares similares